Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. [electronic resource]
Producer: 20140808Description: 3205-17 p. digitalISSN:- 1538-7445
- Animals
- Antigen-Presenting Cells -- drug effects
- Antineoplastic Agents -- pharmacology
- CD4-Positive T-Lymphocytes -- drug effects
- CD40 Ligand -- physiology
- Drug Screening Assays, Antitumor
- Indoles -- pharmacology
- Interferon-gamma -- physiology
- Macrophages -- drug effects
- Melanoma, Experimental -- drug therapy
- Mice
- Mice, Transgenic
- Mutation, Missense
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Signal Transduction
- Skin Neoplasms -- drug therapy
- Sulfonamides -- pharmacology
- Tumor Microenvironment -- immunology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.